<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369486</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-104</org_study_id>
    <secondary_id>U10EY018817-03</secondary_id>
    <secondary_id>U10EY014229-07</secondary_id>
    <secondary_id>U10EY014231-09</secondary_id>
    <nct_id>NCT00369486</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema</brief_title>
  <acronym>Peribulbar</acronym>
  <official_title>A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves the enrollment of patients over 18 years of age with diabetic macular
      edema involving the center of the macula who have not already been given maximal laser
      treatment.

      Patients with one study eye will be randomly assigned (stratified by prior laser) with equal
      probability to one of five treatment groups:

        1. Focal laser photocoagulation (modified ETDRS technique)

        2. Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)

        3. Anterior peribulbar injection of 20 mg triamcinolone

        4. Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser

        5. Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser

      For patients with two study eyes (both eyes eligible at the time of randomization), the right
      eye (stratified by prior laser) will be randomly assigned with equal probabilities to one of
      the five treatment groups listed above. If the right eye was assigned to laser only, then the
      left eye will be assigned to one of the four triamcinolone groups above with equal
      probability (stratified by prior laser). If the right eye was assigned to receive
      triamcinolone, then the left eye will receive laser only.

      Triamcinolone acetonide will be the corticosteroid utilized in this study. The triamcinolone
      acetonide preparation to be used is Kenalog. Kenalog is manufactured by Bristol Myers Squibb
      and is approved by the Food and Drug Administration for intramuscular use for a variety of
      indications. Peribulbar injections of Kenalog have been used for a wide variety of ocular
      conditions, particularly uveitis and post-cataract extraction cystoid macular edema, for many
      years.

      Two different triamcinolone regimens will be assessed in the study: 40 mg injected
      posteriorly and 20 mg injected anteriorly. There is no indication of which treatment regimen
      will be better. Although the injection behind the eye is more common than the injection near
      the front of the eye, the injection near the front of the eye has less risk of injuring the
      eye. However, it is possible that the injection near the front of the eye may increase eye
      pressure more frequently. Little is known about which of the two injections decreases macular
      edema and improves vision more often.

      Patients enrolled into the study will be followed for three years and will have study visits
      1 month, 2 months, 4 months, 8 months and annually after receiving their assigned study
      treatment. For the first 8 months of the study, patients should only be retreated with their
      randomized treatment. However, if the patient's visual acuity has decreased by 15 letters or
      more, then any treatment may be given at the investigator's discretion. After completion of
      the 8-month visit, treatment is at investigator discretion.

      The primary objective of this study is to obtain estimates of efficacy and safety outcomes
      for each of the treatment groups. These estimates will provide a basis for the sample size
      estimation and hypothesis generation in a phase III trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy is a major cause of visual impairment in the United States. Diabetic
      macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central
      vision. Data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) estimate
      that after 15 years of known diabetes, the prevalence of diabetic macular edema is
      approximately 20% in patients with type 1 diabetes mellitus (DM), 25% in patients with type 2
      DM who are taking insulin, and 14% in patients with type 2 DM who do not take insulin.

      Diabetic macular edema results from abnormal leakage of macromolecules, such as lipoproteins,
      from retinal capillaries into the extravascular space followed by an oncotic influx of water
      into the extravascular space. Abnormalities in the retinal pigment epithelium may also cause
      or contribute to diabetic macular edema. These abnormalities may allow increased fluid from
      the choriocapillaries to enter the retina or they may decrease the normal efflux of fluid
      from the retina to the choriocapillaris. The mechanism of breakdown of the blood retina
      barrier at the level of the retinal capillaries and the retinal pigment epithelium may be due
      to changes to tight junction proteins such as occludin.

      The increase in retinal capillary permeability and subsequent retinal edema may be the result
      of a breakdown of the blood retina barrier mediated in part by vascular endothelial growth
      factor (VEGF), a 45 kD glycoprotein. Aiello et al, demonstrated in an in vivo model that VEGF
      can increase vascular permeability. Fifteen eyes of 15 albino Sprague-Dawley rats received an
      intravitreal injection of VEGF. The effect of intravitreal administration of VEGF on retinal
      vascular permeability was assessed by vitreous fluorophotometry. In all 15 eyes receiving an
      intravitreal injection of VEGF, a statistically significant increase in vitreous fluorescein
      leakage was recorded. In contrast, control eyes, which were fellow eyes injected with vehicle
      alone, did not demonstrate a statistically significant increase in vitreous fluorescein
      leakage. Vitreous fluorescein leakage in eyes injected with VEGF attained a maximum of 227%
      of control levels.

      Antonetti et al, demonstrated that VEGF may regulate vessel permeability by increasing
      phosphorylation of tight junction proteins such as occludin and zonula occluden 1.
      Sprague-Dawley rats were given intravitreal injections of VEGF and changes in tight junction
      proteins were observed through Western blot analysis. Treatment with alkaline phosphatase
      revealed that these changes were caused by a change in phosphorylation of tight junction
      proteins. This model provides, at the molecular level, a potential mechanism for
      VEGF-mediated vascular permeability in the eye. Similarly, in human non-ocular disease states
      such as ascites, VEGF has been characterized as a potent vascular permeability factor (VPF).

      The normal human retina contains little or no VEGF; however, hypoxia causes upregulation of
      VEGF production. Vinores et al, using immunohistochemical staining for VEGF, demonstrated
      that increased VEGF staining was found in retinal neurons and retinal pigment epithelium in
      human eyes with diabetic retinopathy.

      As the above discussion suggests, attenuation of the effects of VEGF provides a rationale for
      treatment of macular edema associated with diabetic retinopathy. Corticosteroids, a class of
      substances with anti-inflammatory properties, have been demonstrated to inhibit the
      expression of the VEGF gene. In a study by Nauck et al, the platelet-derived growth-factor
      (PDGF) induced expression of the VEGF gene in cultures of human aortic vascular smooth muscle
      cells was abolished by corticosteroids in a dose-dependent manner. A separate study by Nauck
      et al demonstrated that corticosteroids abolished the induction of VEGF by the
      pro-inflammatory mediators PDGF and platelet-activating factor (PAF) in a time and
      dose-dependent manner. This study was performed using primary cultures of human pulmonary
      fibroblasts and pulmonary vascular smooth muscle cells.

      As discussed above, corticosteroids have been experimentally shown to down regulate VEGF
      production and possibly reduce breakdown of the blood-retinal barrier. Similarly, steroids
      have anti-angiogenic properties possibly due to attenuation of the effects of VEGF. Both of
      these steroid effects have been utilized. For example, triamcinolone acetonide is often used
      clinically as a periocular injection for the treatment of cystoid macular edema (CME)
      secondary to uveitis or as a result of intraocular surgery. In animal studies, intravitreal
      triamcinolone acetonide has been used in the prevention of proliferative vitreoretinopathy
      and retinal neovascularization. Intravitreal triamcinolone acetonide has been used clinically
      in the treatment of proliferative vitreoretinopathy and choroidal neovascularization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Central Subfield Thickening From Baseline Through 34 Weeks</measure>
    <time_frame>4, 8, 17, 34 weeks</time_frame>
    <description>Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. Negative changes represent a decrease in retinal thickening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Acuity Letter Score From Baseline Through 34 Weeks</measure>
    <time_frame>4, 8, 17, and 34 weeks</time_frame>
    <description>Change in visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the electronic Early Treatment for Diabetic Retinopathy Study(E-ETDRS) technique. Letter score best value = 97 and worst value = 0; an increase in a letter score by 10 is considered clinically significant. Negative changes represent a worsening in visual acuity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Visual Acuity Letter Score at Each Follow-up Visit</measure>
    <time_frame>4, 8, 17, and 34 weeks</time_frame>
    <description>Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) mean visual acuity letter score: best value = 97; letter score worst value = 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks</measure>
    <time_frame>17 weeks</time_frame>
    <description>Number of eyes that were retreated at 17 weeks. According to the protocol, primary criterion for retreatment was central subfield thickness &gt;=250 microns or macular edema was still present according to the investigator's judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks</measure>
    <time_frame>4, 8, 17, 34 weeks</time_frame>
    <description>Number of eyes that had a reduction in central subfield retinal thickness by ≥ 50% at each follow-up. Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness &lt;250 Microns From Baseline Through 34 Weeks</measure>
    <time_frame>4, 8, 17, 34 weeks</time_frame>
    <description>Primary criterion for retreatment is central subfield thickness &gt;=250 microns. Central subfield thickness of &lt;250 microns indicates no need for retreatment. Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Focal laser photocoagulation</intervention_name>
    <description>Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>focal/grid laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40mg triamcinolone</intervention_name>
    <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Kenalog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20mg triamcinolone</intervention_name>
    <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Kenalog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40mg triamcinolone + laser</intervention_name>
    <description>Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Kenalog</other_name>
    <other_name>focal/grid photocoagulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20mg triamcinolone + laser</intervention_name>
    <description>Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Kenalog</other_name>
    <other_name>focal/grid photocoagulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Level Criteria Inclusion

        To be eligible, the following inclusion criteria (1-4) must be met:

          1. Age ≥18 years

          2. Diagnosis of diabetes mellitus (type 1 or type 2)

          3. At least one eye meets the study eye criteria

          4. Able and willing to provide informed consent.

             Study Level Exclusion Criteria

             A patient is not eligible if any of the following exclusion criteria (5-13) are
             present:

          5. History of chronic renal failure requiring dialysis or kidney transplant.

          6. A condition that, in the opinion of the investigator, would preclude participation in
             the study (e.g., unstable medical status including blood pressure and glycemic
             control). Patients in poor glycemic control who, within the last 4 months, initiated
             intensive insulin treatment (a pump or multiple daily injections) or plan to do so in
             the next 4 months should not be enrolled.

          7. Participation in an investigational trial within 30 days of study entry that involved
             treatment with any drug that has not received regulatory approval at the time of study
             entry.

          8. Known allergy to any corticosteroid or any component of the delivery vehicle.

          9. History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids within 4
             months prior to randomization or topical, rectal, or inhaled corticosteroids in
             current use more than 2 times per week.

         10. History of steroid-induced intraocular pressure elevation that required IOP-lowering
             treatment in either eye.

         11. Warfarin (coumadin) currently being used.

         12. Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110). If blood
             pressure is brought below 180/110 by anti-hypertensive treatment, patient can become
             eligible.

         13. Patient is expecting to move out of the area of the clinical center to an area not
             covered by another clinical center during the next 8 months.

             The patient must have at least one eye meeting all of the inclusion criteria (a-e) and
             none of the exclusion criteria (f-t) listed below:

             Study Eye Inclusion Criteria

               1. Best corrected electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS)
                  visual acuity score of ≥69 letters (i.e., 20/40 or better).

               2. Definite retinal thickening due to diabetic macular edema based on clinical exam.

               3. Retinal thickness in the Optical Coherence Tomography (OCT) central subfield
                  measuring 250 microns or more.

               4. Maximal laser has not already been given and investigator believes that either
                  peribulbar steroids or laser may benefit the eye (note: subjects may be enrolled
                  without having received prior macular laser).

               5. Media clarity, pupillary dilation, and patient cooperation sufficient for
                  adequate fundus photographs and OCT.

                  Study Eye Exclusion Criteria

               6. Macular edema is considered to be due to a cause other than diabetic macular
                  edema.

               7. An ocular condition is present such that, in the opinion of the investigator,
                  visual acuity would not improve from resolution of macular edema (e.g., foveal
                  atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal
                  condition).

               8. An ocular condition is present (other than diabetes) that, in the opinion of the
                  investigator, might affect macular edema or alter visual acuity during the course
                  of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease,
                  neovascular glaucoma, Irvine-Gass Syndrome, etc.).

               9. History of prior treatment with intravitreal, peribulbar, or retrobulbar
                  corticosteroids for DME.

              10. History of focal/grid macular photocoagulation within 15 weeks (3.5 months) prior
                  to randomization. Note: Patients are not required to have had prior macular
                  photocoagulation to be enrolled.

              11. History of panretinal scatter photocoagulation (PRP) within 4 months prior to
                  randomization or anticipated need for PRP in the 4 months following
                  randomization.

             m. History of prior vitrectomy.

             n. History of major ocular surgery (including cataract extraction, scleral buckle, any
             intraocular surgery, etc.) within prior 6 months or anticipated within the next 6
             months following randomization.

             o. History of YAG capsulotomy performed within 2 months prior to randomization.

             p. Intraocular pressure ≥25 mmHg.

             q. History of open-angle glaucoma (either primary open-angle glaucoma or other cause
             of open-angle glaucoma; note: angle-closure glaucoma is not an exclusion). A history
             of ocular hypertension is not an exclusion as long as (1) intraocular pressure is &lt;25
             mm Hg, (2) the patient is using no more than one topical glaucoma medication, (3) the
             most recent visual field, performed within the last 12 months, is normal (if
             abnormalities are present on the visual field they must be attributable to the
             patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous.
             Note: if the intraocular pressure is 22 to &lt;25 mm Hg, then the above criteria for
             ocular hypertension eligibility must be met.

             r. History of prior herpetic ocular infection.

             s. Exam evidence of ocular toxoplasmosis.

             t. Exam evidence of pseudoexfoliation.

             A patient may have two &quot;study eyes&quot; only if both are eligible at the time of
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Chew, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <reference>
    <citation>Chew EY, Glassman AR, Beck RW, Bressler NM, Fish GE, Ferris FL, Kinyoun JL; Diabetic Retinopathy Clinical Research Network. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina. 2011 Feb;31(2):284-9. doi: 10.1097/IAE.0b013e3181f049a8.</citation>
    <PMID>20948459</PMID>
  </reference>
  <results_reference>
    <citation>Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, Beck R, Aiello LP, Antoszyk A, Bressler N, Browning D, Danis R, Fan J, Flaxel C, Friedman S, Glassman A, Kollman C, Lazarus H. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology. 2007 Jun;114(6):1190-6.</citation>
    <PMID>17544778</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2006</study_first_submitted>
  <study_first_submitted_qc>August 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>October 14, 2009</results_first_submitted>
  <results_first_submitted_qc>May 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2011</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <name_title>Roy W. Beck, M.D., Ph.D., Director</name_title>
    <organization>Jaeb Center for Health Research (DRCR.net)</organization>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>macular</keyword>
  <keyword>edema</keyword>
  <keyword>peribulbar</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>acetonide</keyword>
  <keyword>laser</keyword>
  <keyword>photocoagulation</keyword>
  <keyword>intraocular</keyword>
  <keyword>DME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-two clinical sites across the United States recruited 129 eyes of 109 subjects between December 2004 and September 2005. 113 subjects were randomized, but 4 were not included in any of the analysis because they were ineligible.</recruitment_details>
      <pre_assignment_details>Participants with two study eyes enrolled each eye in a different treatment group. Therefore, each treatment group/arm includes no more than one study eye for a given participant, and thus the numbers of eyes is equal to the number of participants in each arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Focal Laser Photocoagulation</title>
          <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
        </group>
        <group group_id="P2">
          <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
          <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
        </group>
        <group group_id="P3">
          <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
          <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
        </group>
        <group group_id="P4">
          <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
          <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
        </group>
        <group group_id="P5">
          <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
          <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>4-Week Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="21">Number of eyes</participants>
                <participants group_id="P3" count="23">Number of eyes</participants>
                <participants group_id="P4" count="22">Number of eyes</participants>
                <participants group_id="P5" count="25">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36">Number of eyes</participants>
                <participants group_id="P2" count="19">Number of eyes;</participants>
                <participants group_id="P3" count="22">Number of eyes</participants>
                <participants group_id="P4" count="20">Number of eyes</participants>
                <participants group_id="P5" count="24">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dropped</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>8-Week Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="21">Number of eyes</participants>
                <participants group_id="P3" count="22">Number of eyes</participants>
                <participants group_id="P4" count="22">Number of eyes</participants>
                <participants group_id="P5" count="25">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="20">Number of eyes</participants>
                <participants group_id="P3" count="22">Number of eyes</participants>
                <participants group_id="P4" count="21">Number of eyes</participants>
                <participants group_id="P5" count="24">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dropped</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>17-Week Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="21">Number of eyes</participants>
                <participants group_id="P3" count="23">Number of eyes</participants>
                <participants group_id="P4" count="22">Number of eyes</participants>
                <participants group_id="P5" count="25">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="21">Number of eyes</participants>
                <participants group_id="P3" count="22">Number of eyes</participants>
                <participants group_id="P4" count="21">Number of eyes</participants>
                <participants group_id="P5" count="24">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>34-Week Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="21">Number of eyes</participants>
                <participants group_id="P3" count="23">Number of eyes</participants>
                <participants group_id="P4" count="22">Number of eyes</participants>
                <participants group_id="P5" count="25">Number of eyes that</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">Number of eyes</participants>
                <participants group_id="P2" count="20">Number of eyes</participants>
                <participants group_id="P3" count="22">Number of eyes</participants>
                <participants group_id="P4" count="19">Number of eyes</participants>
                <participants group_id="P5" count="22">Number of eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dropped</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Focal Laser Photocoagulation</title>
          <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
        </group>
        <group group_id="B2">
          <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
          <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
        </group>
        <group group_id="B3">
          <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
          <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
        </group>
        <group group_id="B4">
          <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
          <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
        </group>
        <group group_id="B5">
          <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
          <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="11"/>
                    <measurement group_id="B2" value="58" spread="12"/>
                    <measurement group_id="B3" value="60" spread="8"/>
                    <measurement group_id="B4" value="64" spread="7"/>
                    <measurement group_id="B5" value="63" spread="13"/>
                    <measurement group_id="B6" value="60" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cystoid Abnormality on Ocular Coherence Tomography (OCT)</title>
          <units>eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Type</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity</title>
          <description>Best corrected visual acuity letter score as measured by a certified tester using an electronic early treatment diabetic retinopathy study (e-ETDRS) method and approximate Snellen equivalent. Best value on the scale is 97, worst value 0.</description>
          <units>eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=79: 20/25 or better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>78-69: 20/32-20/40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Received Prior Focal Photocoagulation</title>
          <units>eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Received Prior Scatter (Panretinal) Photocoagulation</title>
          <units>eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subretinal Fluid on Ocular Coherence Tomography (OCT)</title>
          <description>Ocular Coherence Tomography (OCT) images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
          <units>eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Subfield Thickness</title>
          <description>Measured by Ocular Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324" spread="70"/>
                    <measurement group_id="B2" value="321" spread="53"/>
                    <measurement group_id="B3" value="342" spread="79"/>
                    <measurement group_id="B4" value="319" spread="59"/>
                    <measurement group_id="B5" value="336" spread="58"/>
                    <measurement group_id="B6" value="328" spread="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <description>N=129 eyes</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" spread="10"/>
                    <measurement group_id="B2" value="14" spread="9"/>
                    <measurement group_id="B3" value="15" spread="7"/>
                    <measurement group_id="B4" value="16" spread="7"/>
                    <measurement group_id="B5" value="15" spread="9"/>
                    <measurement group_id="B6" value="15" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.7"/>
                    <measurement group_id="B2" value="7.3" spread="1.6"/>
                    <measurement group_id="B3" value="8.1" spread="1.7"/>
                    <measurement group_id="B4" value="7.8" spread="1.3"/>
                    <measurement group_id="B5" value="7.5" spread="1.8"/>
                    <measurement group_id="B6" value="7.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular Pressure (mm Hg)</title>
          <description>N=129 eyes</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="3"/>
                    <measurement group_id="B2" value="16" spread="4"/>
                    <measurement group_id="B3" value="16" spread="4"/>
                    <measurement group_id="B4" value="16" spread="3"/>
                    <measurement group_id="B5" value="17" spread="3"/>
                    <measurement group_id="B6" value="16" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean visual acuity letter score</title>
          <description>Baseline Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) Visual Acuity Letter Score: best value = 97; letter score worst value = 0</description>
          <units>letter score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="5"/>
                    <measurement group_id="B2" value="79" spread="4"/>
                    <measurement group_id="B3" value="81" spread="5"/>
                    <measurement group_id="B4" value="79" spread="7"/>
                    <measurement group_id="B5" value="78" spread="6"/>
                    <measurement group_id="B6" value="79" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Retinal Volume (mm^3)</title>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.2"/>
                    <measurement group_id="B2" value="7.6" spread="0.9"/>
                    <measurement group_id="B3" value="8.1" spread="1.2"/>
                    <measurement group_id="B4" value="7.8" spread="0.6"/>
                    <measurement group_id="B5" value="7.9" spread="0.8"/>
                    <measurement group_id="B6" value="8.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Central Subfield Thickening From Baseline Through 34 Weeks</title>
        <description>Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. Negative changes represent a decrease in retinal thickening.</description>
        <time_frame>4, 8, 17, 34 weeks</time_frame>
        <population>Last Observation Carried Forward was used. The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal Laser Photocoagulation</title>
            <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
          </group>
          <group group_id="O2">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
          </group>
          <group group_id="O3">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
          </group>
          <group group_id="O4">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
          <group group_id="O5">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Subfield Thickening From Baseline Through 34 Weeks</title>
          <description>Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. Negative changes represent a decrease in retinal thickening.</description>
          <population>Last Observation Carried Forward was used. The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="53"/>
                    <measurement group_id="O2" value="-47" spread="51"/>
                    <measurement group_id="O3" value="-27" spread="36"/>
                    <measurement group_id="O4" value="-16" spread="60"/>
                    <measurement group_id="O5" value="-37" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27" spread="49"/>
                    <measurement group_id="O2" value="-29" spread="62"/>
                    <measurement group_id="O3" value="-38" spread="44"/>
                    <measurement group_id="O4" value="-25" spread="55"/>
                    <measurement group_id="O5" value="-44" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30" spread="60"/>
                    <measurement group_id="O2" value="-24" spread="91"/>
                    <measurement group_id="O3" value="-50" spread="49"/>
                    <measurement group_id="O4" value="-52" spread="45"/>
                    <measurement group_id="O5" value="-49" spread="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54" spread="62"/>
                    <measurement group_id="O2" value="-31" spread="113"/>
                    <measurement group_id="O3" value="-45" spread="56"/>
                    <measurement group_id="O4" value="-45" spread="70"/>
                    <measurement group_id="O5" value="-68" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in central subfield thickening from baseline to 34 weeks in all five groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>Adjusted for baseline central subfield thickness</p_value_desc>
            <method>repeated measures least sq. regression</method>
            <method_desc>Models adjusted for baseline values and for correlated data from subjects with two study eyes.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks</title>
        <description>Number of eyes that were retreated at 17 weeks. According to the protocol, primary criterion for retreatment was central subfield thickness &gt;=250 microns or macular edema was still present according to the investigator's judgment.</description>
        <time_frame>17 weeks</time_frame>
        <population>The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit</population>
        <group_list>
          <group group_id="O1">
            <title>Focal Laser Photocoagulation</title>
            <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
          </group>
          <group group_id="O2">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
          </group>
          <group group_id="O3">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
          </group>
          <group group_id="O4">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
          <group group_id="O5">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks</title>
          <description>Number of eyes that were retreated at 17 weeks. According to the protocol, primary criterion for retreatment was central subfield thickness &gt;=250 microns or macular edema was still present according to the investigator's judgment.</description>
          <population>The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eyes that were retreated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes with ≥ 250 central subfield thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis combined posterior and anterior injection + laser groups to compare with laser only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>generalized estimating equations</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis combined posterior and anterior injection only groups to compare with laser only treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>generalized estimating equations</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Acuity Letter Score From Baseline Through 34 Weeks</title>
        <description>Change in visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the electronic Early Treatment for Diabetic Retinopathy Study(E-ETDRS) technique. Letter score best value = 97 and worst value = 0; an increase in a letter score by 10 is considered clinically significant. Negative changes represent a worsening in visual acuity.</description>
        <time_frame>4, 8, 17, and 34 weeks</time_frame>
        <population>The primary analysis included all randomized eyes and followed the intent-to-treat analysis. The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal Laser Photocoagulation</title>
            <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
          </group>
          <group group_id="O2">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
          </group>
          <group group_id="O3">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
          </group>
          <group group_id="O4">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
          <group group_id="O5">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity Letter Score From Baseline Through 34 Weeks</title>
          <description>Change in visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the electronic Early Treatment for Diabetic Retinopathy Study(E-ETDRS) technique. Letter score best value = 97 and worst value = 0; an increase in a letter score by 10 is considered clinically significant. Negative changes represent a worsening in visual acuity.</description>
          <population>The primary analysis included all randomized eyes and followed the intent-to-treat analysis. The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit.</population>
          <units>letter score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="5"/>
                    <measurement group_id="O2" value="1" spread="4"/>
                    <measurement group_id="O3" value="-1" spread="4"/>
                    <measurement group_id="O4" value="-2" spread="6"/>
                    <measurement group_id="O5" value="-1" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="5"/>
                    <measurement group_id="O2" value="0" spread="7"/>
                    <measurement group_id="O3" value="-1" spread="6"/>
                    <measurement group_id="O4" value="0" spread="4"/>
                    <measurement group_id="O5" value="0" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="5"/>
                    <measurement group_id="O2" value="-1" spread="6"/>
                    <measurement group_id="O3" value="-2" spread="5"/>
                    <measurement group_id="O4" value="-1" spread="7"/>
                    <measurement group_id="O5" value="-1" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="12"/>
                    <measurement group_id="O2" value="-4" spread="11"/>
                    <measurement group_id="O3" value="-1" spread="5"/>
                    <measurement group_id="O4" value="-3" spread="15"/>
                    <measurement group_id="O5" value="-1" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of the mean change in visual acuity letter score among the five groups at 34 weeks. Negative changes represent a worsening in visual acuity.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>repeated measures least sq. regression</method>
            <method_desc>Adjusted for baseline values and for the correlated data from subjects with two study eyes.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Visual Acuity Letter Score at Each Follow-up Visit</title>
        <description>Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) mean visual acuity letter score: best value = 97; letter score worst value = 0</description>
        <time_frame>4, 8, 17, and 34 weeks</time_frame>
        <population>The primary analysis included all randomized eyes and followed the intent-to-treat analysis. The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal Laser Photocoagulation</title>
            <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
          </group>
          <group group_id="O2">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
          </group>
          <group group_id="O3">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
          </group>
          <group group_id="O4">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
          <group group_id="O5">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Acuity Letter Score at Each Follow-up Visit</title>
          <description>Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) mean visual acuity letter score: best value = 97; letter score worst value = 0</description>
          <population>The primary analysis included all randomized eyes and followed the intent-to-treat analysis. The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit.</population>
          <units>letter score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="5"/>
                    <measurement group_id="O2" value="79" spread="5"/>
                    <measurement group_id="O3" value="80" spread="6"/>
                    <measurement group_id="O4" value="77" spread="7"/>
                    <measurement group_id="O5" value="77" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="5"/>
                    <measurement group_id="O2" value="79" spread="6"/>
                    <measurement group_id="O3" value="80" spread="7"/>
                    <measurement group_id="O4" value="80" spread="7"/>
                    <measurement group_id="O5" value="77" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="6"/>
                    <measurement group_id="O2" value="78" spread="5"/>
                    <measurement group_id="O3" value="79" spread="7"/>
                    <measurement group_id="O4" value="79" spread="7"/>
                    <measurement group_id="O5" value="77" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="12"/>
                    <measurement group_id="O2" value="76" spread="12"/>
                    <measurement group_id="O3" value="80" spread="8"/>
                    <measurement group_id="O4" value="77" spread="16"/>
                    <measurement group_id="O5" value="77" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks</title>
        <description>Number of eyes that had a reduction in central subfield retinal thickness by ≥ 50% at each follow-up. Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
        <time_frame>4, 8, 17, 34 weeks</time_frame>
        <population>The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit</population>
        <group_list>
          <group group_id="O1">
            <title>Focal Laser Photocoagulation</title>
            <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
          </group>
          <group group_id="O2">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
          </group>
          <group group_id="O3">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
          </group>
          <group group_id="O4">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
          <group group_id="O5">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks</title>
          <description>Number of eyes that had a reduction in central subfield retinal thickness by ≥ 50% at each follow-up. Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
          <population>The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Subfield Thickness &lt;250 Microns From Baseline Through 34 Weeks</title>
        <description>Primary criterion for retreatment is central subfield thickness &gt;=250 microns. Central subfield thickness of &lt;250 microns indicates no need for retreatment. Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
        <time_frame>4, 8, 17, 34 weeks</time_frame>
        <population>The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit</population>
        <group_list>
          <group group_id="O1">
            <title>Focal Laser Photocoagulation</title>
            <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
          </group>
          <group group_id="O2">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
          </group>
          <group group_id="O3">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
          </group>
          <group group_id="O4">
            <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
            <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
          <group group_id="O5">
            <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
            <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
          </group>
        </group_list>
        <measure>
          <title>Central Subfield Thickness &lt;250 Microns From Baseline Through 34 Weeks</title>
          <description>Primary criterion for retreatment is central subfield thickness &gt;=250 microns. Central subfield thickness of &lt;250 microns indicates no need for retreatment. Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology.</description>
          <population>The correlation between eyes of patients who have two study eyes (one eye in the laser group and one eye in either of the Triamcinolone groups) was accounted for in the primary analysis. Primary analyses excluded patients who missed the visit</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Focal Laser Photocoagulation</title>
          <description>Modified Early Treatment diabetic retinopathy Study technique (m-ETDRS, Laser burns-50 microns, gray intensity Multiple settings (all completed in single setting).</description>
        </group>
        <group group_id="E2">
          <title>Posterior Peribulbar Injection of 40 mg Triamcinolone</title>
          <description>Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)</description>
        </group>
        <group group_id="E3">
          <title>Anterior Peribulbar Injection of 20 mg Triamcinolone</title>
          <description>Anterior peribulbar injection of 20 mg triamcinolone</description>
        </group>
        <group group_id="E4">
          <title>Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser</title>
          <description>Posterior peribulbar injection of 40 mg triamcinolone followed by focal photocoagulation after one month</description>
        </group>
        <group group_id="E5">
          <title>Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser</title>
          <description>Anterior peribulbar injection of 20 mg triamcinolone followed by focal photocoagulation after one month</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13"/>
                <counts group_id="E2" subjects_affected="11"/>
                <counts group_id="E3" subjects_affected="7"/>
                <counts group_id="E4" subjects_affected="5"/>
                <counts group_id="E5" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative or localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteomyelities acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer or skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54"/>
                <counts group_id="E2" subjects_affected="53"/>
                <counts group_id="E3" subjects_affected="60"/>
                <counts group_id="E4" subjects_affected="23"/>
                <counts group_id="E5" subjects_affected="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HbA1c (increase by 0.5% or more from baseline)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Elevated intraocular pressure/glaucoma (increase by 10mm Hg or more at any visit)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Subconjunctival haemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam R. Glassman, M.S., Director</name_or_title>
      <organization>Jaeb Center for Health Research, Diabetic Retinopathy Clinical Research Network</organization>
      <phone>(813) 975-8690</phone>
      <email>drcrnet@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

